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Background: Recent in vitro and in vivo studies have suggested a critical role of osteocalcin (OC), especially the
undercarboxylated form (ucOC), in insulin secretion and insulin sensitivity. The objective of this study was to
investigate the association between serum ucOC levels and insulin resistance in humans with type 2 diabetes
mellitus.
Findings: We measured serum ucOC levels in 129 patients with type 2 diabetes. Insulin resistance was assessed
using the euglycemic hyperinsulinemic clamp technique. The insulin resistance indices used were the M value,
which is the total body glucose disposal rate, and the M/I value, which is the M value adjusted for the steady state
plasma insulin level. ucOC levels were not correlated with the M value (ρ = −0.013, p = 0.886) or the M/I value
(ρ = 0.001, p = 0.995).
Conclusions: We found no association between ucOC levels and insulin resistance in patients with type 2 diabetes
mellitus.
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Emerging evidence has shed light on the role of bone as
an endocrine organ that regulates energy metabolism
[1,2]. Among its intermediate factors, bone-derived
osteocalcin (OC) has attracted much attention. Recent
vigorous studies have demonstrated that OC regulates
both insulin secretion and insulin sensitivity [3-5].
Clinically, serum OC level is utilized as a bone formation
marker, because OC is synthesized by osteoblast [1].
Therefore, vitamin-K dependent gamma-carboxylated OC,
which binds to hydroxyapatite in bone [1], has been consid-
ered to be active in bone metabolism. Intriguingly, in vitro
and in vivo studies have clearly demonstrated that under-
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reproduction in any medium, provided the ormetabolism in rodents [3-5]. Most studies in humans have
suggested that higher OC levels are associated with better
metabolic profiles as assessed by cretain parameters, such
as fasting plasma glucose (FPG), hemoglobin A1c (HbA1c),
the homeostasis model assessment (HOMA)–β, and the
HOMA of insulin resistance (HOMA-IR) [1,2]. However,
data that examines the correlation between ucOC kevels
and glucose metabolism is limited. Kanazawa et al. reported
that ucOC levels were negatively associated with FPG and
HbA1c [6]. Focusing on insulin resistance, one report sug-
gested that total OC and carboxylated OC levels, and not
ucOC levels, were associated with the HOMA-IR [7]. In
contrast, Iki et al. found an inverse correlation between
ucOC levels and the HOMA-IR [8]. These contradictory
findings may have arisen from methodological limitations
in their approaches for evaluating insulin resistance and
the particular cohorts examined, which were basically
designated for osteoporosis research.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics and insulin resistance
parameters measured with the hyperinsulinemic
euglycemic clamp technique in subjects with type 2
diabetes
Age (years) 54.9 ± 12.3
Sex (Ma/Fe) 79/50
Duration of Diabetes (years) 6.0 (2.0–12.0)
BMI (kg/m2) 25.2 ± 2.8
SBP (mmHg) 127 ± 18
FPG (mg/dL) 134 (117–160)
HbA1c (%) 9.0 ± 2.2
TC (mg/dL) 196 ± 32
HDL (mg/dL) 43 (35–51)
TG (mg/dL) 122 (92–159)
sCre (mg/dl) 0.71 ± 0.17
M (mg·kg-1·min-1) 4.6 (2.8–5.7)
SSPI (μU/mL) 104 (86–127)
M/I value (mg·kg-1·min-1·mU-1·L×100) 4.0 (2.4–6.1)
All values are expressed as mean ± SD, n, or median (interquartile range). BMI:
body mass index, SBP: systolic blood pressure, FPG: fasting plasma glucose, TC:
total cholesterol, HDL: high density lipoprotein, TG: triglyceride, sCre: serum
creatinine, M: glucose infusion rate, SSPI: steady state plasma insulin, M/I value:
defined by dividing M by SSPI and multiplying by 100.
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are associated with insulin resistance in patients with
type 2 diabetes using M and M/I values, which are gold
standard indices for measuring insulin resistance, using
the euglycemic hyperinsulinemic clamp technique.
Methods
A total of 129 subjects were selected from participants
admitted our diabetes center at Osaka City University
Hospital. Patients with serum creatinine levels >1.2 mg/dL
(106 μmol/L) and other active medical diseases were
excluded. Of the 129 patients selected, 65 were taking
the following medications: insulin (n = 15), sulfonylureas
(n = 29), α-glucosidase inhibitors (n = 5), biguanides



















Figure 1 The association between serum ucOC levels and M (A) and M
levels and M (ρ = −0.013, p = 0.886) and M/I values (ρ = 0.001, p = 0.995).(n= 2), and combination therapies of these drugs (n = 10).
The study protocol was approved by the local ethics
committee, and informed consent was obtained from
all participants prior to study initiation.
HbA1c (%) levels were estimated as National Glycohe-
moglobin Standardization Program equivalent values (%)
and were calculated by the formula HbA1c (%) = HbA1c
(JDS;%) + 0.4%, considering the relative expression of
HbA1c (%) as measured by standard laboratory methods
and previous Japanese standard materials [9]. ucOC levels
were measured by electrochemiluminescence immunoassay
(Picolumi ucOC, Sanko Junyaku Co. Ltd., Tokyo, Japan) [6]
[8]. Insulin resistance was assessed by the euglycemic
hyperinsulinemic clamp using an STG 22 artificial pancreas
model (Nikkiso Co., Tokyo), as described previously
[10,11]. The total body glucose disposal rate was deter-
mined as the mean of the glucose infusion rate (M) during
the last 30 minutes of the clamp. The insulin resistance
index (M/I value) was calculated by dividing the mean M
by the steady state plasma insulin level during the last 30
minutes of the clamp and multiplying by 100. All values are
reported as mean ± the standard deviation (SD unless
otherwise indicated. Because the ucOC, M, and M/I values
were not normally distributed, we used Spearman rank
correlation test to study the association between the
ucOC, M, and M/I values. The Mann–Whitney U test was
used to compare ucOC levels between male and female
subjects. P values of <0.05 were considered statistically
significant.
Results
Clinical characteristics of the subjects are summarized in
Table 1. Median ucOC levels were 3.7 ng/mL (interquar-
tile range [IQ], 2.2-5.1) and ranged from 0.4 to 23.1 ng/
mL. The median M values and M/I values were 4.6 (IQ,
2.8-5.7; range, 1.1 to 10.8) mg·kg-1·min-1 and 4.0 (IQ,
2.4-6.1; range, 0.7 to 16.9) mg·kg-1·min-1·mU-1·L×100,
respectively. ucOC levels were not correlated with either

































/I values (B). There was no significant association of serum ucOC
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ucOC levels were significantly lower in males than in
females (males, 3.4[IQ, 2.0-4.6]; females, 4.2[IQ, 2.9-5.9];
p = 0.018), we divided all patients into two groups by
sex and examined the association between ucOC levels
and M values and M/I values. We found that ucOC
levels were not correlated with M values in both males
(ρ = −0.077, p = 0.500) and females (ρ = 0.065, p = 0.650).
There was also no correlation between ucOC levels and
M/I values in both males (ρ = −0.052, p = 0.648) and
females (ρ = 0.068, p = 0.632).
Discussion
This is the first study, as per our knowledge, to examine
the association between ucOC levels and insulin resist-
ance using the euglycemic clamp technique, which is the
gold standard method for evaluating insulin resistance in
humans. We found no significant correlation between
ucOC levels and insulin resistance in patients with type
2 diabetes. These findings suggest that it is premature to
conclude that ucOC plays a role in glucose metabolism
in humans.
The HOMA-IR is easily calculated from fasting insulin
and glucose levels and is commonly used for the evalu-
ation of insulin resistance in clinical practice. However,
some attention needs to paid to the interpretation of
these values as indices of insulin resistance because they
mainly depend on the balance between hepatic glucose
output and insulin secretion, which is maintained by a
feedback loop between the liver and pancreatic β-cells
[12]. In particular, the HOMA-IR may not be a good
tool for this purpose because ucOC levels appear to
affect both insulin secretion and insulin sensitivity con-
currently. On the other hand, M/I values predominantly
represent insulin resistance in insulin-sensitive organs,
such as skeletal muscle and adipose tissue, but not in
the liver. This is because insulin reaches approximate
level of 100 μU/mL under euglycemic hyperinsulinemic
clamp procedures; therefore, they can almost completely
suppress hepatic glucose output [10,11]. Indeed, the
average plasma insulin level achieved in our study was
104 μU/mL (Table 1). Therefore, M/I values are accurate
and quantitative in the assessment of insulin resistance,
primarily in skeletal muscle, and are independent of insulin
secretion capacity in humans. However, this procedure is
time-consuming, costly, and complicated.
Administration of recombinant ucOC into mice clearly
enhanced both insulin secretion and sensitivity [3-5].
However, its impact on glucose metabolism in humans
remains unclear. Although we targeted subjects with
apparent type 2 diabetes, this may confound the inter-
action between ucOC levels and insulin resistance. For
example, diabetes has been linked to dysregulated bone
metabolism [2]. Another possible confounding factormay be treatment with antidiabetic drugs. Insulin regu-
lates the function of osteoblasts and the production of
OC/ucOC [2]. Furthermore, a recent longitudinal study
in elderly men, including those with diabetes, showed
that the increase in ucOC levels was associated with
improvements in the HOMA-IR, and this association
was limited to subjects who were not treated with
antidiabetic drugs [13]. Therefore, aberrant glucose
metabolism, drug interventions or both may make it
more difficult to interrupt the correlation between ucOC
levels and insulin resistance. In this regard, Iki et al.
clearly showed a significant inverse association between
ucOC levels and the HOMA-IR in community-based
population without apparent health problems [8]. If the
effect of ucOC on glucose metabolism is not comparable
to that of strong influential factors such as adiponectin,
which is a key player in energy metabolism [14], cohort
selection may be critical in confirming the association
between ucOC levels and insulin secretion and sensitivity.
The present study had several limitations. First was
the cross-sectional study design and the relatively-small
sample size. Second, there was no information regarding
medications for metabolic bone diseases, including
vitamin K, which up-regulates gamma-carboxylation of
OC. Third, we did not measure total OC levels. However,
the ucOC/OC ratio may be a more relevant measure.
Finally, although we hypothesized that ucOC could affect
insulin sensitivity via adiponectin, serum adiponctin levels
were not determined.
In conclusion, we found no association between ucOC
levels and insulin resistance in patients with type 2 diabetes
as per the euglycemic hyperinsulinemic clamp technique.
Further studies are required to confirm the impact of
ucOC, OC, and ucOC/OC ratio on insulin resistance in
humans.
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